Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002723 · ClinicalTrials.gov registry record · Phase 3
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
- 20
- Study locations
NCT00002723: Completed Phase 3 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).
NCT00002723 is a Phase 3 study of Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 390 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002723, a Phase 3 study of Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of suramin is more effective for prostate cancer.
Primary Outcome
PSA levels
Conditions Studied
Interventions
- DRUG Suramin
- DRUG suramin
Study Locations (20)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- CCOP - Carle Cancer Center - Urbana
Minnesota
- CCOP - Duluth - Duluth
- Veterans Affairs Medical Center - Minneapolis - Minneapolis
- CCOP - Metro-Minnesota - Saint Louis Park
Michigan
- CCOP - Ann Arbor Regional - Ann Arbor
- CCOP - Kalamazoo - Kalamazoo
New Jersey
- Veterans Affairs Medical Center - East Orange - East Orange
- CCOP - Northern New Jersey - Hackensack
Ohio
- Ireland Cancer Center - Cleveland
- CCOP - Toledo Community Hospital Oncology Program - Toledo
Pennsylvania
- CCOP - Geisinger Clinic and Medical Center - Danville
- CCOP - MainLine Health - Wynnewood
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 1996-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00002723 record still lists
NCT00002723 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Suramin is the first listed.
NCT00002723 names 20 study sites across 12 states, led by Illinois, Minnesota, Michigan.
Frequently Asked Questions
What is clinical trial NCT00002723 about?
NCT00002723 is a clinical study titled "Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer". Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is ...
What is the current status of trial NCT00002723?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 1996-01. Estimated completion is 2008-03.
What conditions does trial NCT00002723 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00002723?
The interventions under investigation include: Suramin (DRUG), suramin (DRUG).
Who is sponsoring clinical trial NCT00002723?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002723 being conducted?
This trial has 20 study locations across Illinois, Iowa, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002723's enrollment target sits among peer trials
390 137th of 735 higher than 599 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia